Milk-derived exosomes for oral delivery of paclitaxel

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 13, Issue 5, 2017, Pages 1627-1636

  Agrawal, Ashish K ^a   Aqil, Farrukh ^a,b   Jeyabalan, Jeyaprakash ^b   Spencer, Wendy A ^c   Beck, Joshua ^c   Gachuki, Beth W ^d   Alhakeem, Sara S ^d   Oben, Karine ^d   Munagala, Radha ^a,b   Bondada, Subbarao ^d   Gupta, Ramesh C ^a,b,c  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

^c 3P Biotechnologies Inc   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Antitumor efficacy; Exosomes; Immunological responses; Lung cancer; Systemic toxicity; Taxol

Indexed keywords

BIOLOGICAL ORGANS; DRUG PRODUCTS; PARTICLE SIZE; PARTICLE SIZE ANALYSIS; TUMORS;

ANTI-TUMOR EFFICACY; EXOSOMES; IMMUNOLOGICAL RESPONSE; LUNG CANCER; SYSTEMIC TOXICITIES; TAXOL;

TOXICITY;

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; PACLITAXEL; ANTINEOPLASTIC AGENT;

ARTICLE; ATOMIC FORCE MICROSCOPY; BONE MARROW CELL; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; EXOSOME; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLUID; LUNG TUMOR; MILK; MOUSE; NONHUMAN; PARTICLE SIZE; SUSTAINED DRUG RELEASE; TUMOR XENOGRAFT; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ZETA POTENTIAL; ANIMAL; LUNG NEOPLASMS; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; EXOSOMES; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MILK; PACLITAXEL;

EID: 85019709730     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2017.03.001     Document Type: Article

References (38)

1. Rowinsky, E.K., Donehower, R.C., Paclitaxel (taxol). N Engl J Med 332 (1995), 1004–1014.
2. Gelderblom, H., Verweij, J., Nooter, K., Sparreboom, A., Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37 (2001), 1590–1598.
3. Sparreboom, A., Scripture, C.D., Trieu, V., Williams, P.J., De, T., Yang, A., et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol). Clin Cancer Res 11 (2005), 4136–4143.
4. Gradishar, W.J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23 (2005), 7794–7803.
5. Bawarski, W.E., Chidlowsky, E., Bharali, D.J., Mousa, S.A., Emerging nanopharmaceuticals. Nanomedicine 4 (2008), 273–282.
6. Aisner, J., Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health 64 (2007), S4–S7.
7. Joo, K.M., Park, K., Kong, D.S., Song, S.Y., Kim, M.H., Lee, G.S., et al. Oral paclitaxel chemotherapy for brain tumors: ideal combination treatment of paclitaxel and P-glycoprotein inhibitor. Oncol Rep 19 (2008), 17–23.
8. Torne, S.J., Ansari, K.A., Vavia, P.R., Trotta, F., Cavalli, R., Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. Drug Deliv 17 (2010), 419–425.
9. Ma, P., Mumper, R.J., Paclitaxel nano-delivery systems: a comprehensive review. J Nanomed Nanotechol, 4, 2013, 1000164.
10. Munagala, R., Aqil, F., Jeyabalan, J., Gupta, R.C., Bovine milk-derived exosomes for drug delivery. Cancer Lett 371 (2016), 48–61.
11. Kim, M.S., Haney, M.J., Zhao, Y., Mahajan, V., Deygen, I., Klyachko, N.L., et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 12 (2016), 655–664.
12. Izumi, H., Kosaka, N., Shimizu, T., Sekine, K., Ochiya, T., Takase, M., Bovine milk contains microRNA and messenger RNA that are stable under degradative conditions. J Dairy Sci 95 (2012), 4831–4841.
13. Aqil, F., Kausar, H., Agrawal, A.K., Jeyabalan, J., Kyakulaga, A.H., Munagala, R., et al. Exosomal formulation enhances therapeutic response of celastrol against lung cancer. Exp Mol Pathol 101 (2016), 12–21.
14. Marques, M.R.C., Loebenberg, R., Almukainzi, M., Simulated biological fluids with possible application in dissolution testing. Dissolut Technol 18 (2011), 15–28.
15. Estrella, V., Chen, T., Lloyd, M., Wojtkowiak, J., Cornnell, H.H., Ibrahim-Hashim, A., et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res 73 (2013), 1524–1535.
16. Yang, T., Cui, F.D., Choi, M.K., Cho, J.W., Chung, S.J., Shim, C.K., et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm 338 (2007), 317–326.
17. Koziara, J.M., Lockman, P.R., Allen, D.D., Mumper, R.J., Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 99 (2004), 259–269.
18. Fernandez, A., De Arriba, F., Rivera, J., Heras, I., Vicente, V., Lozano, M.L., Successful mobilization of hematopoietic peripheral blood progenitor cells with paclitaxel-based chemotherapy as initial or salvage regimen in patients with hematologic malignancies. Haematologica 93 (2008), 1436–1438.
19. Shea, T.C., Mobilization of peripheral blood progenitor cells with paclitaxel-based chemotherapy. Semin Oncol, 1997.
20. Perera, P.Y., Qureshi, N., Vogel, S.N., Paclitaxel (Taxol)-induced NF-kappaB translocation in murine macrophages. Infect Immun 64 (1996), 878–884.
21. Malingre, M.M., Beijnen, J.H., Schellens, J.H., Oral delivery of taxanes. Invest New Drugs 19 (2001), 155–162.
22. Lee, J., Lee, S.C., Acharya, G., Chang, C.J., Park, K., Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property. Pharm Res 20 (2003), 1022–1030.
23. Konno, T., Watanabe, J., Ishihara, K., Enhanced solubility of paclitaxel using water-soluble and biocompatible 2-methacryloyloxyethyl phosphorylcholine polymers. J Biomed Mater Res A 65 (2003), 209–214.
24. Beijnen, J.H., Huizing, M.T., ten Bokkel, H.W., Veenhof, C., Vermorken, J.B., Giaccone, G., et al. Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol). Semin Oncol, 1994.
25. Joshi, N., Saha, R., Shanmugam, T., Balakrishnan, B., More, P., Banerjee, R., Carboxymethyl-chitosan-tethered lipid vesicles: hybrid nanoblanket for oral delivery of paclitaxel. Biomacromolecules 14 (2013), 2272–2282.
26. Jain, S., Kumar, D., Swarnakar, N.K., Thanki, K., Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials 33 (2012), 6758–6768.
27. Calleja, P., Espuelas, S., Vauthier, C., Ponchel, G., Irache, J.M., Controlled release, intestinal transport, and oral bioavailablity of paclitaxel can be considerably increased using suitably tailored pegylated poly(anhydride) nanoparticles. J Pharm Sci 104 (2015), 2877–2886.
28. Bothiraja, C., Thorat, U.H., Pawar, A.P., Shaikh, K.S., Chitosan coated layered clay montmorillonite nanocomposites modulate oral delivery of paclitaxel in colonic cancer. Mater Technol 29 (2014), B120–B126.
29. Bhardwaj, V., Ankola, D.D., Gupta, S.C., Schneider, M., Lehr, C.M., Kumar, M.N., PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm Res 26 (2009), 2495–2503.
30. Peltier, S., Oger, J.M., Lagarce, F., Couet, W., Benoit, J.P., Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res 23 (2006), 1243–1250.
31. Pandita, D., Ahuja, A., Lather, V., Benjamin, B., Dutta, T., Velpandian, T., et al. Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. AAPS PharmSciTech 12 (2011), 712–722.
32. Tiwari, S.B., Amiji, M.M., Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J Nanosci Nanotechnol 6 (2006), 3215–3221.
33. Ganta, S., Amiji, M., Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 6 (2009), 928–939.
34. Agrawal, A.K., Harde, H., Thanki, K., Jain, S., Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. Biomacromolecules 15 (2014), 350–360.
35. Hoque, M., Dave, S., Gupta, P., Saleemuddin, M., Oleic acid may be the key contributor in the BAMLET-induced erythrocyte hemolysis and tumoricidal action. PLoS One, 8, 2013, e68390.
36. Liskova, K., Kelly, A.L., O'Brien, N., Brodkorb, A., Effect of denaturation of alpha-lactalbumin on the formation of BAMLET (bovine alpha-lactalbumin made lethal to tumor cells). J Agric Food Chem 58 (2010), 4421–4427.
37. Rammer, P., Groth-Pedersen, L., Kirkegaard, T., Daugaard, M., Rytter, A., Szyniarowski, P., et al. BAMLET activates a lysosomal cell death program in cancer cells. Mol Cancer Ther 9 (2010), 24–32.
38. Kreuter, J., Peroral administration of nanoparticles. Adv Drug Deliver Rev 7 (1991), 71–86.